UK Sanders-Brown Center on Aging

What if a failed leukemia drug could reduce the risk of Alzheimer’s disease? A team at the University of Kentucky recently led an effort to investigate this hypothesis. Their results were published today in the journal, Human Molecular Genetics.

A new clinical trial being conducted at the University of Kentucky Sanders-Brown Center on Aging (SBCoA) and the UK Alzheimer’s Disease Center (ADC) may signal new hope in the future for those who might be afflicted with the devastating disease.

Singer, physician, athlete and inspirational speaker Dr. Ronan Tynan is no stranger to adversity. When Tynan was 20, his legs had to be amputated below the knee after an auto accident caused serious complications. Just weeks after the operation, he was climbing up the steps of his college dorm, and within a year, he was winning gold medals in the Paralympics as a multitalented athlete.

Even a mild injury to the brain can have long lasting consequences, including increased risk of cognitive impairment later in life. While it is not yet known how brain injury increases risk for dementia, there are indications that chronic, long-lasting, inflammation in the brain may be important.

A study by a leading Alzheimer's researcher at the University of Kentucky provides new evidence that will help researchers home in on the molecular mechanisms involved in inflammation of the central nervous system (CNS) and aid drug-development strategies for treating inflammatory neurological diseases.

A research team composed of University of Kentucky researchers has published a paper which provides the first direct evidence that activated astrocytes could play a harmful role in Alzheimer's disease. The UK Sanders-Brown Center on Aging has also received significant new National Institutes of Health (NIH) funding to further this line of study.

Subscribe to RSS - UK Sanders-Brown Center on Aging